Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Deucravacitinib→

Deucravacitinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1609392-27-9
Molecular formula
C20H19D3N8O3
Molecular weight
425.47 g/mol
Drug class
Tyrosine Kinase 2 Inhibitor
Mechanism of action
Tyrosine Kinase 2 Inhibitors [MoA]
Indications / reported uses
  • Parapsoriasis
  • moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • active psoriatic arthritis in adults

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Deucravacitinib Environmental Risk Assessment (ERA) (the Deucravacitinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.